[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-460262-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-460262-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","prognostic-value-of-highsensitivity-troponin-i-for-cardiovascular-risk-stratification-in-chronic-kidney-disease-patients","Prognostic Value of High‑Sensitivity Troponin I for Cardiovascular Risk Stratification in Chronic Kidney Disease Patients","","Chronic kidney disease is associated with elevated cardiovascular morbidity and mortality, while conventional risk assessment methods often fail to capture this group’s cardiovascular risk adequately. A prospective observational study evaluated whether high‑sensitivity cardiac troponin I (hs‑cTnI) can identify subclinical myocardial damage and predict major adverse cardiovascular events in CKD patients. Among 120 non‑dialysis CKD stage 3–5 patients followed for 12 months, elevated hs‑cTnI significantly increased MACE incidence and independently predicted outcomes.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-value-of-highsensitivity-troponin-i-for-cardiovascular-risk-stratification-in-chronic-kidney-disease-patients/460262/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-value-of-highsensitivity-troponin-i-for-cardiovascular-risk-stratification-in-chronic-kidney-disease-patients/460262.png","ImageObject",300,407,{"name":42,"@type":43},"Mafia Boss","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What was the study aim regarding hs‑cTnI in chronic kidney disease patients?","Question",{"text":62,"@type":63},"To assess whether high‑sensitivity cardiac troponin I reflects subclinical myocardial damage and can predict major adverse cardiovascular events during follow‑up.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How many patients were included, and what was the follow‑up period?",{"text":67,"@type":63},"The study included 120 adult CKD patients (stage 3 to 5, excluding dialysis patients) and followed them for 12 months for major adverse cardiovascular events.",{"name":69,"@type":60,"acceptedAnswer":70},"Did elevated hs‑cTnI predict major adverse cardiovascular events?",{"text":71,"@type":63},"Yes. A significantly higher proportion of MACE occurred in the elevated hs‑cTnI group than in the normal group, and Cox regression showed hs‑cTnI as an independent predictor of MACE.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},460262,1790758105,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":79,"read_time":111,"preview_page_count":30,"preview_urls":143},962090760730,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Original Research  \nPrognostic Value of High‑Sensitivity Troponin I for Cardiovascular Risk Stratification in Chronic Kidney Disease Patients  \nMrinal Kunj1, Prabin Kumar Shrivastava1, Prashant Kumar1, Anshu Kumar2  \n1Department of Cardiology, RIMS, Ranchi, Jharkhand, India, 2Department of Pharmacology, Manipal Tata Medical College, Jamshedpur, Jharkhand, India  \nSubmitted: 10‑Jul‑2025  \nRevised: 02‑Aug‑2025  \nAccepted: 08‑Aug‑2025  \nPublished: 17‑Dec‑2025  \nAbstract  \nBackground: The onset of chronic kidney disease (CKD) results in a high level of cardiovascular morbidity and mortality. Conventional risk assessment systems tend to fail in considering the cardiovascular risk of this group of people. A biomarker of myocardial damage, high‑sensitivity cardiac troponin I (hs‑cTnI), has become a candidate biomarker of subclinical cardiac damage. Materials and Methods: A prospective observational study was carried out of 120 patients with CKD stages 3 to 5 that excluded dialysis patients. A high‑sensitivity immunoassay was used to measure the baseline value of hs‑cTnI. The follow‑up was thorough, with patients being kept under observation after 12 months of occurrence in their patients major adverse cardiovascular events (MACE), i.e., myocardial infarction, heart failure hospitalization, and cardiovascular death. Results: Out of 120 CKD patients (mean age 58.2+/‑ 9.6 years; 62 males), 48 patients (40%) had elevated hs‑cTnI (>19.0 ng/L) . The number of patients who developed MACE at the time of the follow‑up was 29 (24.2%) . There was a significantly greater proportion of MACE in an elevated hs‑cTnI group (52.1%) than in a normal hs‑cTnI group (10.4%) (P \u003C 0.001) . The Cox regression analysis indicated that an independent outcome predictor of MACE was hs‑cTnI (HR 3.89, 95% CI 1.91793, P = 0.002) . The ROC area under the curve of hs‑cTnI at predicting MACE was 0.81 (95% CI 0.7290) . Conclusion: High‑sensitivity T‑I is a good prognostic biomarker of cardiovascular events among CKD patients. Its regular evaluation can help in the initial classification of risks and selective cardiovascular preventive interventions.  \nKeywords: Biomarkers, cardiovascular risk, chronic kidney disease,  \nhigh‑sensitivity troponin I, major adverse cardiovascular events   \nIntroduction  \nAcurrent  \nkidney  \nworldwide public health problem, chronic disease (CKD), has shown a significantly  \nhigher prevalence of cardiovascular disease (CVD) risk; it has been observed as the preeminent cause of morbidity and mortality among this group.[1] The traditional cardiovascular risk factors like hypertension, diabetes, and dyslipidemia cannot explain the impacted cardiovascular burden in CKD, implying that there must be other nontraditional biomarkers that can provide complementary predictors of the risk.[2] Biomarkers that are in the fresh outlook include cardiac troponins because they can establish subclinical myocardial damages.  \n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code:\u003Cbr>| Website: [https://journals.lww.com/jpbs](https://journals.lww.com/jpbs) |\n|  | DOI: 10.4103/jpbs.jpbs_1204_25 |\n\nThe sensitivity of high‑sensitivity cardiac troponin I (hs‑cTnI) assays enables small traces of troponin in the blood to be found, and therefore, myocardial stress or injury may be identified in unfortunate cases that have shown no symptoms.[3] The levels of hs‑cTnI are raised in those patients with CKD because they had no overt ischemic heart disease, bringing up the questions concerning the pathophysiological processes associated with this elevation and the prognostic impact of this  \n\n| Address for correspondence: Dr. Prashant Kumar, Department of Cardiology, RIMS, Ranchi, Jharkhand, India.\u003Cbr>E‑mail: [prashant87897@gmail.com](prashant87897@gmail.com) |\n| --- |\n| This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License (CC BY-NC-ND), where it is permissible to download and ","cbCaib4CiOdMeAdQ","https://ap.wps.com/l/cbCaib4CiOdMeAdQ","pdf",564376,"English","# Abstract\n# Introduction\n# Materials and Methods\n# Results\n# Conclusion","[{\"question\":\"What was the study aim regarding hs‑cTnI in chronic kidney disease patients?\",\"answer\":\"To assess whether high‑sensitivity cardiac troponin I reflects subclinical myocardial damage and can predict major adverse cardiovascular events during follow‑up.\"},{\"question\":\"How many patients were included, and what was the follow‑up period?\",\"answer\":\"The study included 120 adult CKD patients (stage 3 to 5, excluding dialysis patients) and followed them for 12 months for major adverse cardiovascular events.\"},{\"question\":\"Did elevated hs‑cTnI predict major adverse cardiovascular events?\",\"answer\":\"Yes. A significantly higher proportion of MACE occurred in the elevated hs‑cTnI group than in the normal group, and Cox regression showed hs‑cTnI as an independent predictor of MACE.\"}]","Prognostic Value of High‑Sensitivity Troponin I for Cardiovascular Risk Stratification in Chronic Kidney Disease Patients | PDF",[144,148,152],{"page_no":22,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/ed24d613e9c5f20a732225a839a60631.webp",983,1272,{"page_no":26,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/5fc966c3a612e3a167ed70934e11a685.webp",982,1270,{"page_no":30,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/b2710e3c5d6887ebe2696f72e42adb18.webp",981,1269]